Literature DB >> 3709630

Effect of carbamazepine on psychomotor performance in näive subjects.

G J MacPhee, C Goldie, D Roulston, L Potter, E Agnew, J Laidlaw, M J Brodie.   

Abstract

The effect of a single dose of carbamazepine (CBZ), 10 mg kg-1, on a battery of simple psychomotor tests was investigated in 12 healthy subjects (6 male, 6 female) in a balanced randomised double blind placebo controlled cross-over study. Psychomotor testing and blood sampling for total and free plasma CBZ, and CBZ 10, 11 epoxide concentration were performed at 10, 12, 14, 16, 18 and 34 h after oral dosing (23.00 h the previous evening). CBZ impaired i) critical flicker fusion threshold frequency at all time points up to 18 h (p less than 0.005); ii) total choice reaction time at 10 h (p less than 0.005) and 18 h (p less than 0.008); iii) card sorting at 14 h (p less than 0.001). No significant effect on finger tapping was noted. Subjects adjudged themselves more sedated on CBZ as compared to placebo at 12, 14 and 16 h (p less than 0.008). Plasma total and free CBZ concentrations (mean +/- SD) peaked at 10 h (8.8 +/- 0.2 mg 1-1) and 16 h (1.88 +/- 0.3 mg 1-1) after dosing respectively. CBZ 10, 11 epoxide values were all less than 10% of total CBZ concentrations and, therefore, were unlikely to contribute to the pharmacodynamic effect. Total choice reaction time was significantly more impaired in females (p less than 0.05) but no sex difference occurred with the other tests or CBZ concentrations at any time point. No significant correlations were found between individual total or free CBZ concentrations and corresponding test performances at each time point.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3709630     DOI: 10.1007/bf00614193

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Anticonvulsant drugs.

Authors:  D L Davidson
Journal:  Br Med J (Clin Res Ed)       Date:  1983-06-25

2.  Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects.

Authors:  R Riva; F Albani; G Ambrosetto; M Contin; P Cortelli; E Perucca; A Baruzzi
Journal:  Epilepsia       Date:  1984-08       Impact factor: 5.864

Review 3.  Psychomotor function and psychoactive drugs.

Authors:  I Hindmarch
Journal:  Br J Clin Pharmacol       Date:  1980-09       Impact factor: 4.335

4.  The effects of carbamazepine on patients with psychomotor epilepsy: results of a double-blind study.

Authors:  E A Rodin; C S Rim; P M Rennick
Journal:  Epilepsia       Date:  1974-12       Impact factor: 5.864

5.  Correlation between daily fluctuations of carbamazepine serum levels and intermittent side effects.

Authors:  R J Höppener; A Kuyer; J W Meijer; J Hulsman
Journal:  Epilepsia       Date:  1980-08       Impact factor: 5.864

6.  The influence of carbamazepine and phenytoin on memory and other aspects of cognitive function in new referrals with epilepsy.

Authors:  D G Andrewes; L Tomlinson; R D Elwes; E H Reynolds
Journal:  Acta Neurol Scand Suppl       Date:  1984

7.  Effects of cimetidine on carbamazepine auto- and hetero-induction in man.

Authors:  G J Macphee; G G Thompson; G Scobie; E Agnew; B K Park; T Murray; K E McColl; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

8.  Anticonvulsant drugs and cognitive functions.

Authors:  P J Thompson; M R Trimble
Journal:  Epilepsia       Date:  1982-10       Impact factor: 5.864

9.  Psychotropic effects of carbamazepine in epilepsy: a double-blind comparison with phenytoin.

Authors:  C B Dodrill; A S Troupin
Journal:  Neurology       Date:  1977-11       Impact factor: 9.910

10.  Anticonvulsant serum levels: relationship to impairments of cognitive functioning.

Authors:  P J Thompson; M R Trimble
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-03       Impact factor: 10.154

View more
  11 in total

1.  Actions of zopiclone and carbamazepine, alone and in combination, on human skilled performance in laboratory and clinical tests.

Authors:  T Kuitunen; M J Mattila; T Seppälä; K Aranko; M E Mattila
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

2.  Computer analysis of saccadic eye movements: assessment of two different carbamazepine formulations.

Authors:  G Tedeschi; G Casucci; S Allocca; R Riva; A Di Costanzo; A Quattrone; A Baruzzi; V Bonavita
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Rapid tolerance to acute psychomotor impairment with carbamazepine in epileptic patients.

Authors:  J G Larkin; P J McKee; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

4.  Comparative pharmacokinetics and pharmacodynamics of eterobarbital and phenobarbital in normal volunteers.

Authors:  N Barzaghi; G Gatti; R Manni; C A Galimberti; C Zucca; E Perucca; A Tartara
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

5.  Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients.

Authors:  P J McKee; J Blacklaw; E Butler; R A Gillham; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

6.  Impairment of psychomotor function at modest plasma concentrations of carbamazepine after administration of the liquid suspension to naive subjects.

Authors:  J D Wildin; B J Pleuvry; G E Mawer
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

7.  Psychomotor impairment and anticonvulsant therapy in adult epileptic patients.

Authors:  M J Brodie; E McPhail; G J Macphee; J G Larkin; J M Gray
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man.

Authors:  G J Macphee; J R Mitchell; L Wiseman; A R McLellan; B K Park; G T McInnes; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

9.  Controlled evaluation of a supplementary dose of carbamazepine on psychomotor function in epileptic patients.

Authors:  G J Macphee; E M McPhail; E Butler; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Concentration-effect relationships with carbamazepine and its epoxide on psychomotor and cognitive function in epileptic patients.

Authors:  R A Gillham; N Williams; K Wiedmann; E Butler; J G Larkin; M J Brodie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-07       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.